You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY23 is not expected to be complete until September, 2024.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
A Randomized, Blinded, Placebo-Controlled Clinical Trial to Evaluate Longeveron Mesenchymal Stem Cell (LMSC) Therapy for Treating The Metabolic Syndrome
SBC: Longeveron LLC Topic: NIAThe metabolic syndrome (MetS) is a cluster of factors that increases the risks for cardiovascular disease, type 2 diabetes mellitus, and mortality, and currently affects andgt; 40% of US adults. MetS is associated with endothelial dysfunction, decreased circulating endothelial progenitor cells (EPCs), and a pro-inflammatory state. We have made the exciting discovery that therapy with allogeneic me ...
STTR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health -
Stem Cells for Treating Acute Stroke
SBC: SANERON CCEL THERAPEUTICS, INC. Topic: 999ABSTRACT SUMMARY In previous studies we identified novel non hematopoietic umbilical cord blood stem cellsnhUCBSCsthat could be expanded to high passages and exhibit restorative properties following ischemic brain injury repairWe found that the high passaged cells were equivalentif not even betterthan the low passaged nh UCBSCsThis finding suggests that these cells can serve as a source of highly ...
STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health -
Rapid Development of a Highly Specific Dengue Diagnostic Test
SBC: Z-Quick, LLC Topic: NIAIDProject Summary Abstract The advent of the Zika virusZIKVepidemic around the world has and will cause problems for the correct diagnosis of flavivirus infectionsFor many yearsDENV serological diagnosis was relatively straightforwardHoweverafter the recent ZIKV epidemiccross reactive antibodiesAbsgenerated after ZIKV infection will bind to DENV even if the patient has never had DENVThe only FDA app ...
STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health -
Compatibility between Brain-Computer Interface and High-Efficiency Augmentative and Alternative Communication Systems
SBC: Prentke Romich Company Topic: NIDCDCompatibility between Brain-Computer Interface and High Efficiency Augmentative and AlternativeCommunication Systems: Phase II ABSTRACT Brain-computer interfaces (BCI) enable text production for people who cannot move, but have only simple communication interfaces and are not widely used. Augmentative and alternative communication (AAC) systems are widely used and give efficient and precise commun ...
STTR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health -
LystaMab Immunotherapy to Inhibit Pericardial Adhesions
SBC: LYST THERAPEUTICS LLC Topic: NHLBISUMMARY Despite significant advances in the surgical and medical management of congenital heart diseasecongenital cardiac anomalies remain a leading cause of death in the newborn periodMost severe forms of congenital heart disease require multiplestaged surgical interventionsA significant source of the heightened morbidity and mortality associated with these operations is the development of cardia ...
STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health -
Extending WAAVES+: An animal and environment-agnostic, automated USV scoring platform for high-throughput social, behavioral, and neuropharmacological studies
SBC: CORNERSTONE RESEARCH GROUP INC Topic: 101Project SummaryUltrasonic vocalizations (USVs) are known to reflect emotional processing, brain neurochemistry and brain function - key observations in animal model studies. Collecting and processing USV data is time-intensive, manual, and costly. Most importantly, it limits researchers’ ability to employ fully effective, and nuanced experimental designs, and is a barrier to entry for other rese ...
STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health -
In Vivo Studies of a Novel HDAC Inhibitor for Treating Hemoglobin Disorders
SBC: Cetya Therapeutics, Inc. Topic: NHLBIPROJECT SUMMARY The β-hemoglobinopathies are prevalent genetic blood diseases with few treatment options. It is estimate that 7% of the worldandapos;s population carries an abnormal hemoglobin gene with 400,000 infants born annually with a severe life threatening hemoglobinopathy. Drug mediated induction of normal, but developmentally silenced, fetal hemoglobin (HbF) expression reduces anemia and ...
STTR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health -
POC Blood Coagulopathy Monitor
SBC: CFD RESEARCH CORPORATION Topic: DHA19A001Traumatic injuries account for 30% of all life years lost in the US and is the leading cause of death for people under 46 years of age. Uncontrolled bleeding or hemorrhage constitute 30-40% of trauma related deaths and are considered to be a major cause o
STTR Phase I 2019 Department of DefenseDefense Health Agency -
Direct-read monitor for airborne viral pathogens
SBC: AEROSOL DEVICES INC Topic: NIAIDAerosolized pathogenssuch as Influenza virusescan spread rapidly and silently throughout a populationcausing severe outbreaks that can be difficult to controlEarly detection of these airborne pathogens is key to controlling outbreaksespecially among vulnerable populations such as in hospitalstreatment centers or nursing homesYet available methods are neither rapidnor portableCurrent methods rely h ...
STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health -
DR?1-MOG as a Next-Generation Immunotherapy for Methamphetamine Use Disorder
SBC: VIROGENOMICS BIODEVELOPMENT INC Topic: R41Methamphetamine use disorder is associated with damage to regions of the brain that control cognitive and psychiatric functionOne third to one half of adults with methamphetamine use disorder experience cognitive impairments and other psychiatric symptoms that significantly impact treatment outcomesincreased relapse and lower treatment retention ratesMounting evidence demonstrates how immune facto ...
STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health